Baker McKenzie advised the shareholders of SpotMe Holding (“SpotMe”), a Lausanne-based company providing end-to-end event technology solutions, in connection with the sale of a majority stake to Swiss Post. SpotMe will continue to operate globally
Tags :Martin Frey
Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Baker McKenzie acted as legal counsel to Artum, the Swiss industrial holding company, on the sale of 100% of their shares to Storskogen, a Swedish privately owned company that acquires and operates well-managed and profitable businesses
Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, successfully closes CHF 100 million (approximately USD 110 million) in Series C financing Round. The financing was co-led by new investors
Baker McKenzie Zurich has acted as counsel to Cimpress in connection with the offering of USD 200 million 7.0% senior notes due 2026.
